Inovio Pharmaceuticals (NASDAQ:INO) Earns "Overweight" Rating from Piper Sandler

Key Points

• Piper Sandler reiterated its “Overweight” rating on Inovio but lowered its price target from $8 to $6; the target implies roughly 349% upside from the current share price.
• Inovio’s third-quarter results missed expectations, with a loss of $0.50 per share versus the $0.21 loss forecast and revenue of $0.30 million versus estimates of $2.27 million.
• VOCERYQ’s approval and launch plans are a potential catalyst: Inovio expects the treatment to launch in early 2027 and reported $80.5 million in offering proceeds to support commercialization, with cash runway projected into late 2027.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report)'s stock had its "overweight" rating reiterated by equities research analysts at Piper Sandler in a research note issued on Wednesday, Benzinga reports. They currently have a $6.00 target price on the biopharmaceutical company's stock, down from their prior target price of $8.00. Piper Sandler's price objective suggests a potential upside of 349.10% from the stock's current price.

Several other brokerages have also commented on INO. Wall Street Zen raised shares of Inovio Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, August 15th. Zacks Research cut shares of Inovio Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Monday, October 12th. HC Wainwright set a $5.00 price objective on shares of Inovio Pharmaceuticals and gave the company a "buy" rating in a report on Monday, November 2nd. Jefferies Financial Group reiterated a "buy" rating and issued a $8.00 target price (up from $3.00) on shares of Inovio Pharmaceuticals in a research report on Friday. Finally, Weiss Ratings cut shares of Inovio Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday, August 13th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Inovio Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $6.33.

Inovio Pharmaceuticals Trading Down 7.9%

Shares of INO opened at $1.34 on Wednesday. The firm has a market cap of $147.20 million, a P/E ratio of -1.53 and a beta of 1.71. Inovio Pharmaceuticals has a 12 month low of $0.56 and a 12 month high of $2.72. The stock's 50 day moving average is $1.18 and its two-hundred day moving average is $1.27.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last announced its earnings results on Tuesday, November 10th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.29). The firm had revenue of $0.30 million during the quarter, compared to analyst estimates of $2.27 million. Equities research analysts forecast that Inovio Pharmaceuticals will post -0.74 EPS for the current year.

Institutional Investors Weigh In On Inovio Pharmaceuticals

A number of large investors have recently modified their holdings of INO. Eversept Partners LP purchased a new position in shares of Inovio Pharmaceuticals in the first quarter worth about $1,802,000. Renaissance Technologies LLC grew its stake in Inovio Pharmaceuticals by 16.4% during the 1st quarter. Renaissance Technologies LLC now owns 643,777 shares of the biopharmaceutical company's stock valued at $1,120,000 after acquiring an additional 90,613 shares in the last quarter. Green Alpha Advisors LLC grew its stake in Inovio Pharmaceuticals by 68.8% during the 3rd quarter. Green Alpha Advisors LLC now owns 114,857 shares of the biopharmaceutical company's stock valued at $140,000 after acquiring an additional 46,802 shares in the last quarter. LexAurum Advisors LLC acquired a new stake in Inovio Pharmaceuticals in the 3rd quarter valued at about $118,000. Finally, Prime Capital Investment Advisors LLC raised its holdings in Inovio Pharmaceuticals by 312.4% in the 3rd quarter. Prime Capital Investment Advisors LLC now owns 70,636 shares of the biopharmaceutical company's stock valued at $86,000 after acquiring an additional 53,510 shares during the last quarter. Hedge funds and other institutional investors own 26.79% of the company's stock.

Key Headlines Impacting Inovio Pharmaceuticals

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: VOCERYQ was approved to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis. Inovio expects the treatment to be available for ordering and shipment about 60 days after approval, with a full commercial launch in the first quarter of 2027. The company says the approval validates its DNA-medicine platform. INOVIO Q3 2026 results and business highlights
• Positive Sentiment: Inovio reported $80.5 million in net proceeds from a recently completed public offering to support VOCERYQ’s launch. It also outlined a cash runway into late Q4 2027 and is targeting a European filing by year-end 2026, which could help support commercialization plans. Inovio cash runway and launch plans
• Neutral Sentiment: The company will participate in the Jefferies Global Healthcare Conference on November 18. The event may provide investor visibility, but no new business developments were announced with the notice. Upcoming investor conferences
• Negative Sentiment: Third-quarter results missed analyst expectations: Inovio reported a loss of $0.50 per share versus the $0.21 loss consensus, while revenue was $0.30 million compared with estimates of $2.27 million. The shortfall could weigh on sentiment even as investors focus on VOCERYQ’s launch prospects. Q3 earnings results

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing DNA medicines, including DNA-based vaccines and immunotherapies designed to treat or prevent infectious diseases, cancers and other serious conditions. The company's platform is intended to stimulate targeted immune responses by delivering DNA medicines into cells. Inovio's product pipeline has included investigational therapies such as INO-3107, a DNA immunotherapy being developed for recurrent respiratory papillomatosis, and other candidates targeting cancer and infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.